Literature DB >> 36104410

Could immunotherapy finally break through in prostate cancer?

Anthony King.   

Abstract

Entities:  

Keywords:  Cancer; Immunology; Therapeutics

Mesh：

Year:  2022        PMID： 36104410     DOI： 10.1038/d41586-022-02861-y

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   69.504


× No keyword cloud information.
  6 in total

1.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

2.  PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.

Authors:  In-Young Jung; Simon F Lacey; Andrew J Rech; Megan M Davis; Carl H June; Joseph A Fraietta; Naomi B Haas; Vivek Narayan; Julie S Barber-Rotenberg; Wei-Ting Hwang; Priti Lal; Erica L Carpenter; Shannon L Maude; Gabriela Plesa; Neha Vapiwala; Anne Chew; Michael Moniak; Ronnie A Sebro; Michael D Farwell; Amy Marshall; Joan Gilmore; Lester Lledo; Karen Dengel; Sarah E Church; Tyler D Hether; Jun Xu; Mercy Gohil; Thomas H Buckingham; Stephanie S Yee; Vanessa E Gonzalez; Irina Kulikovskaya; Fang Chen; Lifeng Tian; Kyle Tien; Whitney Gladney; Christopher L Nobles; Hayley E Raymond; Elizabeth O Hexner; Donald L Siegel; Frederic D Bushman
Journal:  Nat Med       Date:  2022-03-21       Impact factor: 87.241

3.  Androgen receptor activity in T cells limits checkpoint blockade efficacy.

Authors:  Xiangnan Guan; Fanny Polesso; Chaojie Wang; Archana Sehrawat; Reed M Hawkins; Susan E Murray; George V Thomas; Breanna Caruso; Reid F Thompson; Mary A Wood; Christina Hipfinger; Scott A Hammond; Julie N Graff; Zheng Xia; Amy E Moran
Journal:  Nature       Date:  2022-03-23       Impact factor: 69.504

4.  Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.

Authors:  Lawrence Fong; Peter Carroll; Vivian Weinberg; Stephen Chan; Jera Lewis; John Corman; Christopher L Amling; Robert A Stephenson; Jeffrey Simko; Nadeem A Sheikh; Robert B Sims; Mark W Frohlich; Eric J Small
Journal:  J Natl Cancer Inst       Date:  2014-09-24       Impact factor: 13.506

5.  A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.

Authors:  Julie N Graff; Tomasz M Beer; Joshi J Alumkal; Rachel E Slottke; William L Redmond; George V Thomas; Reid F Thompson; Mary A Wood; Yoshinobu Koguchi; Yiyi Chen; Emile Latour; Raymond C Bergan; Charles G Drake; Amy E Moran
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751

6.  Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.

Authors:  James L Gulley; Michael Borre; Nicholas J Vogelzang; Siobhan Ng; Neeraj Agarwal; Chris C Parker; David W Pook; Per Rathenborg; Thomas W Flaig; Joan Carles; Fred Saad; Neal D Shore; Liddy Chen; Christopher R Heery; Winald R Gerritsen; Frank Priou; Niels C Langkilde; Andrey Novikov; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2019-02-28       Impact factor: 44.544
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.